



US009170260B2

(12) **United States Patent**  
**Hazen et al.**

(10) **Patent No.:** **US 9,170,260 B2**  
(45) **Date of Patent:** **\*Oct. 27, 2015**

(54) **MYELOPEROXIDASE, A RISK INDICATOR  
FOR CARDIOVASCULAR DISEASE**

(75) Inventors: **Stanley Hazen**, Pepper Pike, OH (US);  
**Renliang Zhang**, Cleveland, OH (US)

(73) Assignee: **The Cleveland Clinic Foundation**,  
Cleveland, OH (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.  
  
This patent is subject to a terminal dis-  
claimer.

(21) Appl. No.: **11/753,799**

(22) Filed: **May 25, 2007**

(65) **Prior Publication Data**

US 2008/0009020 A1 Jan. 10, 2008

#### **Related U.S. Application Data**

(63) Continuation of application No. 10/039,753, filed on  
Jan. 2, 2002, now Pat. No. 7,223,552.

(60) Provisional application No. 60/259,340, filed on Jan.  
2, 2001, provisional application No. 60/283,462, filed  
on Apr. 12, 2001.

(51) **Int. Cl.**

**G01N 33/573** (2006.01)

**G01N 37/00** (2006.01)

**C12Q 1/28** (2006.01)

(52) **U.S. Cl.**

CPC ..... **G01N 33/573** (2013.01); **C12Q 1/28**  
(2013.01); **G01N 2800/32** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

2,765,299	A *	10/1956	Porsche et al.	530/364
5,122,534	A	6/1992	Loose et al.	
5,731,208	A	3/1998	Heinecke	
5,747,274	A	5/1998	Jackowski	
5,846,959	A *	12/1998	Medford et al.	514/165
5,871,946	A	2/1999	Lucas et al.	
5,874,313	A *	2/1999	Ahotupa	436/71
5,889,042	A	3/1999	MacLean et al.	
5,985,272	A	11/1999	Deby et al.	
6,096,556	A	8/2000	Heinecke	
6,133,039	A	10/2000	Heinecke	
6,268,220	B1	7/2001	Heinecke	
6,893,829	B2 *	5/2005	Nadler et al.	435/7.4
6,953,666	B1	10/2005	Kinkade, Jr. et al.	
7,223,552	B2 *	5/2007	Hazen et al.	435/7.24
2002/0164662	A1	11/2002	Hazen et al.	
2003/0119792	A1	6/2003	Roca	
2004/0115749	A1 *	6/2004	Buchanan	435/7.92
2008/0009020	A1 *	1/2008	Hazen et al.	435/7.4

#### **FOREIGN PATENT DOCUMENTS**

EP	0389381	3/1990
EP	0 418 486	7/1990
WO	96/04311	2/1996
WO	02/48715	6/2002
WO	02/50550	6/2002
WO	02/062207	8/2002

#### **OTHER PUBLICATIONS**

Jialal et al, Clinical Chemistry, vol. 42, No. 4, 498-506, 1996.\*  
Gerber et al, Eur. Jour. Clin. Chem. Clin. Biochem., vol. 34, pp.  
901-908, 1996.\*  
Faymonville et al. "Myeloperoxidase and elastase as markers of  
leukocyte activation during cardiopulmonary bypass in humans" J  
Thorac Cardiovasc Surg 1991; 102: 309-17.\*  
Thukkani et al., "Identification of a-Chloro Fatty Aldehydes and  
Unsaturated Lysophosphatidylcholine Molecular Species in Human  
Atherosclerotic Lesion", Circulation, Dec. 23-30, 2003, pp. 3128-  
3133.  
Shishehbor et al., "Systemic elevations of free radical oxidation  
products of arachidonic acid are associated with angiographic evi-  
dence of coronary artery disease", Free Radical Biology & Medicine  
41, pp. 1678-1683 (2006).  
Podrez et al., "Platelet CD36 links hyperlipidemia, oxidant stress and  
a prothrombotic phenotype", Nature Medicine, vol. 13, No. 9, pp.  
1086-1095, Sep. 2007.  
Hazen et al., "Oxidized Phospholipids as Endogenous Pattern Rec-  
ognition Ligands in Innate Immunity", J of Biological Chemistry,  
vol. 283, No. 23, pp. 15227-15337, Jun. 6, 2008.  
Diaz et al., "Antioxidants and atherosclerotic heart disease", N Engl  
J Med 337: 408-416 (1997).  
Hazen et al., "Synthesis, isolation and characterization of the adduct  
formed in the reaction of p-hydroxyphenylacetaldehyde with the  
amino head group of phosphatidyl ethanolamine and  
phosphatidylserine", Chem Res Toxicol 12: 19-27 (1999b).

(Continued)

*Primary Examiner* — Daniel E Kolker

*Assistant Examiner* — James Rogers

(74) *Attorney, Agent, or Firm* — Tarolli, Sundheim, Covell  
& Tummino LLP

(57) **ABSTRACT**

Diagnostic tests for characterizing an individual's risk of  
developing or having a cardiovascular disease. In one  
embodiment the present diagnostic test comprises determin-  
ing the level of myeloperoxidase (MPO) activity in a bodily  
sample obtained from the individual or test subject. In another  
embodiment, the diagnostic test comprises determining the  
level of MPO mass in a bodily sample obtained from the test  
subject. In another embodiment, the diagnostic test comprises  
determining the level of one or more select MPO-generated  
oxidation products in a bodily sample obtained from the test  
subject. The select MPO-generated oxidation products are  
dityrosine, nitrotyrosine, methionine sulfoxide or an MPO-  
generated lipid peroxidation products. Levels of MPO activ-  
ity, MPO mass, or the select MPO-generated oxidation prod-  
uct in bodily samples from the test subject are then compared  
to a predetermined value that is derived from measurements  
of MPO activity, MPO mass, or the select MPO-generated  
oxidation product in comparable bodily samples obtained  
from the general population or a select population of human  
subjects. Such comparison characterizes the test subject's  
risk of developing CVD.

**4 Claims, 11 Drawing Sheets**